{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018296","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.117506+00:00","generated_at":"2026-06-08T08:37:39.922175+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phibro Animal Health reports Q1 net loss of $8.0M; lowers FY2024 guidance","bullets":["Net sales $231.3M (-1% YoY); net loss $8.0M vs $3.9M net income prior year; diluted loss per share $0.20.","Adjusted EBITDA $18.7M (-16% YoY); adjusted diluted EPS $0.14 (-33%).","Animal Health segment sales up 4% to $160.5M; Mineral Nutrition down 6%; Performance Products down 18%.","FY2024 guidance reduced: net sales $980M-$1.02B, adjusted EBITDA $106M-$112M, adjusted diluted EPS $1.04-$1.16.","Results include $10.4M pension settlement charge, $6.7M FX losses; Israel conflict causing manufacturing disruptions."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018296","json":"https://secwatch.observer/filing/0001558370-23-018296.json","markdown":"https://secwatch.observer/filing/0001558370-23-018296.md","text":"https://secwatch.observer/filing/0001558370-23-018296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837023018296/0001558370-23-018296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837023018296/pahc-20231108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:37:39.922175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34f245672eadf973526948bb7b96004a6e7473bc","claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended September 30, 2023 results: revenue $231.3 million, net income Net loss of $8.0 million, EPS Diluted loss per share of $0.20. Guidance reaffirmed.","evidence_excerpt":"guidance for the year ending June 30, 2024. ​ Highlights for the three months ended September 30, 2023 (compared to the three months ended September 30, 2022) ​ - Net sales of $231.3 million, a decrease of $1.2 million, or 1% - Net loss of $8.0 million, a decrease of $11.9 million - Diluted loss per share of $0.20, a decrease of $0.30 - Adjusted EBITDA of $18.7","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837023018296/0001558370-23-018296-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$231.3 million"},{"label":"Net income","value":"Net loss of $8.0 million"},{"label":"EPS","value":"Diluted loss per share of $0.20"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}